Daily Newsletter

15 February 2024

Daily Newsletter

15 February 2024

SCOPE: Changing protocol language and site actions are key to making trials inclusive

A panel composed by SGM Alliance at the 2024 SCOPE Summit shared their experiences of setting up and running clinical trials that are more inclusive of the LGBTQIA+ community.

Abigail Beaney February 14 2024

Changing the language used in trial protocols and continually conversing with sites are some ways by which trialists can make clinical research more inclusive of the LGBTQIA+ community, say experts.

On the fourth and final day of the 2024 Summit for Clinical Ops Executives (SCOPE) Summit held in Orlando, a panel, composed by SGM Alliance discussed the most important changes that can make clinical trials more inclusive of the community. SGM Alliance is a not for profit company with the aim of promoting inclusive and meaningful participation of sexual and gender minorities (SGM) in changing and improving healthcare.

Shir Netanel, associate director of patient advocacy and clinical trial advocacy for Janssen, spoke about her experience with the company launching a transgender-inclusive Phase III trial for prostate cancer. Netanel mentioned how changing the language to be gender neutral, for example, allowed the protocol and eligibility criteria to include any patients who are affected with prostate cancer, regardless of their gender.

Additionally, Janssen has also created and deployed a toolkit at trial sites to help investigators be more inclusive, she added.

Michel Reid, head of global demographics and diversity at GSK, said that sponsors cannot keep using the same sites for every study if there are issues with inclusivity. However, in some cases, especially with higher performing sites, educating them on better ways to support people in the community can be a big improvement, he added.

On the role of sites in making trials more inclusive, the Healthcare Equality Index is a helpful tool for sponsors when they are choosing sites and can help overcome these kinds of barriers, said Sandra Amaro, head of clinical trial diversity at Pfizer.

Netanel, who is a member of the LGBTQIA+ community, concluded that it is not enough for those of the community to raise these issues and advocate for changes. “There is so much more power when it is not just members of the community talking about this.”

A previous report by the Clinical Trials Arena found that there was a big lack of inclusion of the LGBTQ+ community in trials, partially due to the increase in restrictive LGBTQ+ bills.

Uncover your next opportunity with expert reports

Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close